NYSE:CVM
CEL-SCI Corporation Stock News
$1.27
-0.130 (-9.29%)
At Close: May 17, 2024
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
09:00am, Thursday, 16'th May 2024
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports second quarter fiscal 2024 financial results.
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
09:00am, Wednesday, 08'th May 2024
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI receives FDA go-ahead for its confirmatory study of Multikine in the treatment of head & neck cancer.
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
09:00am, Tuesday, 23'rd Apr 2024
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI appoints Mario Gobbo to its Board of Directors.
Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content
09:00am, Tuesday, 16'th Apr 2024
NEW YORK--(BUSINESS WIRE)--Channel V Media (CVM), a communications strategy and PR firm that builds market momentum for both established enterprises and emerging venture‑backed innovators, today ann
CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
09:00am, Tuesday, 19'th Mar 2024
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI's LEAPS vaccine offers promising new paradigm to treat rheumatoid arthritis: published in Frontiers in Immunology.
CEL-SCI Corporation Issues Letter to Shareholders
08:45am, Wednesday, 06'th Mar 2024
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation issues letter to shareholders.
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
12:00pm, Tuesday, 13'th Feb 2024
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $7.75 million public offering of common stock.
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
08:30am, Friday, 09'th Feb 2024
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces pricing of $7.75 million public offering of common stock.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--European Medicines Agency grants CEL-SCI a waiver of strict pediatric requirements, clearing the path towards marketing authorization for Multikine.
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
08:00am, Friday, 22'nd Dec 2023
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2023 financial results and clinical & corporate developments.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--UK'S National Institute for Health and Care Excellence (NICE) selects Multikine as potential new standard of care for head & neck cancer.
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
04:15pm, Monday, 20'th Nov 2023
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $5 million public offering of common stock.
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
08:30am, Thursday, 16'th Nov 2023
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $5 million offering of common stock.
CEL-SCI Issues Letter to Shareholders
09:20am, Monday, 30'th Oct 2023
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI issues letter to shareholders.
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
08:00am, Tuesday, 24'th Oct 2023
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals.
